31 This finding is easily explained, since the time of discharge is linked primarily to bowel function recovery, removal ... “cystectomy”, “anterior exenteration”, and “bladder cancer”.

Although radical cystectomy is an effective treatment for bladder cancer, it can have negative effects on urinary and sexual function. Lane et al. have performed nerve-sparing and reproductive ...

Complete removal of the bladder (cystectomy) is the treatment of choice. This provides excellent control of the primary tumor and removes all of the primary lymph node drainage and any potential ...

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug Administration (FDA) to treat adults with muscle-invasive bladder cancer ...

The following is a summary of “Health-related quality of life after radical cystectomy for bladder cancer in elderly patients ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder ...

The standard of care for localized MIBC is radical cystectomy, the removal of the entire bladder. While it is typically ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...